Biophytis obtains IND approval to start its phase 2 OBA study in obesity
Biophytis has received Investigational New Drug (IND) approval from the FDA for its phase 2 OBA clinical study in obesity with BIO101...
top of page
Browse by category
Search
Researchers discover neurons in the brain that controls food intake without causing nausea in an animal model
By teasing apart the therapeutic benefits from the adverse effects of glucagon-like peptide-1 receptor (GLP1R) agonists, researchers from...
Journal Watch 10/7/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...
Patients receiving tirzepatide were significantly more likely to achieve clinically meaningful weight loss compared with those treated receiving semaglutide
Individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight...
Novel regulatory mechanism governing reactive oxygen species production associated with metabolic and immune pathway interactions in obesity
A novel regulatory mechanism governing reactive oxygen species (ROS) production in macrophages in response to energy overload, in which...
GLP-1RA may reduce the risk of specific obesity-associated cancers
Glucagon-like peptide 1 receptor agonists (GLP-1RA) may reduce the risk of specific obesity-associated cancers, according to a study by...
Most Americans do not use GLP-1s long enough to see meaningful weight-loss
The largest study to date has reported that despite the explosion in demand for GLP-1s, 58% of patients discontinue use before reaching a...
Research animation explores first-hand experiences of receiving online support for eating disorders
During the COVID-19 pandemic, many healthcare services were transitioned to run remotely - for example via video calls - creating...
New framework for diagnosing obesity based on body fat distribution not BMI
A new framework for the diagnosis, staging and management of obesity in adults, launched by the European Association for the Study of...
Zhejiang Doer Biologics completes enrolment of the Phase 1b/2a trial evaluating DR10624 in people with obesity with modest hypertriglyceridemia
Zhejiang Doer Biologics has completed the enrolment in the Phase 1b/2a trial evaluating DR10624 in people with obesity with modest...
Browse by tag
bottom of page